X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (3719) 3719
humans (3662) 3662
female (2829) 2829
middle aged (2646) 2646
male (2584) 2584
oncology (2529) 2529
aged (2425) 2425
cancer (2161) 2161
chemotherapy (2070) 2070
chemoradiotherapy (2063) 2063
radiotherapy (1992) 1992
adult (1934) 1934
surgery (1615) 1615
treatment outcome (1531) 1531
care and treatment (1223) 1223
neoplasm staging (1147) 1147
retrospective studies (1039) 1039
antineoplastic combined chemotherapy protocols - therapeutic use (945) 945
aged, 80 and over (930) 930
survival (928) 928
disease-free survival (893) 893
radiation-therapy (864) 864
carcinoma (807) 807
prognosis (774) 774
medicine & public health (756) 756
analysis (722) 722
radiology, nuclear medicine & medical imaging (672) 672
radiation therapy (669) 669
radiation (667) 667
neoadjuvant therapy (659) 659
combined modality therapy (647) 647
hematology, oncology and palliative medicine (629) 629
chemoradiation (617) 617
research (611) 611
survival rate (591) 591
colorectal cancer (563) 563
chemoradiotherapy - adverse effects (562) 562
chemoradiotherapy - methods (554) 554
follow-up studies (552) 552
patients (551) 551
therapy (537) 537
risk factors (524) 524
fluorouracil - administration & dosage (519) 519
kaplan-meier estimate (513) 513
health aspects (511) 511
antineoplastic combined chemotherapy protocols - adverse effects (506) 506
cisplatin (504) 504
cisplatin - administration & dosage (501) 501
rectal neoplasms - pathology (498) 498
rectal cancer (491) 491
squamous-cell carcinoma (488) 488
rectal neoplasms - therapy (474) 474
chemotherapy, adjuvant (472) 472
toxicity (470) 470
chemoradiotherapy, adjuvant (461) 461
trial (459) 459
randomized-trial (456) 456
adenocarcinoma (447) 447
adenocarcinoma - therapy (438) 438
carcinoma, squamous cell - therapy (436) 436
survival analysis (426) 426
time factors (425) 425
radiotherapy dosage (423) 423
adjuvant treatment (417) 417
metastasis (417) 417
esophageal cancer (404) 404
cancer therapies (399) 399
prospective studies (394) 394
gastroenterology & hepatology (384) 384
concurrent chemoradiotherapy (375) 375
fluorouracil (370) 370
patient outcomes (369) 369
squamous cell carcinoma (367) 367
carcinoma, squamous cell - pathology (364) 364
tumors (361) 361
young adult (361) 361
adjuvant chemotherapy (360) 360
clinical trials (352) 352
adenocarcinoma - pathology (351) 351
oncology, experimental (333) 333
cancer patients (331) 331
multivariate analysis (321) 321
antineoplastic agents - therapeutic use (311) 311
radiotherapy, adjuvant (311) 311
phase-iii trial (309) 309
rectal neoplasms - surgery (304) 304
total mesorectal excision (304) 304
chemoradiotherapy, adjuvant - adverse effects (302) 302
esophageal neoplasms - therapy (302) 302
carcinoma, squamous cell - mortality (293) 293
nuclear radiation (288) 288
radiology (284) 284
deoxycytidine - analogs & derivatives (282) 282
head and neck cancer (276) 276
capecitabine (268) 268
preoperative chemoradiotherapy (268) 268
neoadjuvant therapy - methods (263) 263
lymphatic metastasis (260) 260
neoadjuvant therapy - adverse effects (255) 255
proportional hazards models (254) 254
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4102) 4102
German (21) 21
French (18) 18
Japanese (11) 11
Chinese (5) 5
Russian (5) 5
Hungarian (3) 3
Icelandic (1) 1
Italian (1) 1
Serbian (1) 1
Spanish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 2, pp. 184 - 190
Journal Article
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2012, Volume 82, Issue 2, pp. 809 - 816
Purpose In Radiation Therapy Oncology Group 9704, as previously published, patients with resected pancreatic adenocarcinoma received continuous infusion 5-FU... 
Radiology | Hematology, Oncology and Palliative Medicine | Pancreatic adenocarcinoma | Quality assurance | Radiotherapy | Chemoradiotherapy | Adjuvant therapy | CANCER PATIENTS | QUALITY | STAGE | POSTOPERATIVE RADIOTHERAPY | RANDOMIZED-TRIAL | CELL CARCINOMA | GEMCITABINE | BREAST-CANCER | RECTAL-CANCER | HOSPITAL VOLUME | ONCOLOGY | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | Multivariate Analysis | Chemoradiotherapy - adverse effects | Adenocarcinoma - pathology | Humans | Middle Aged | Male | Fluorouracil - therapeutic use | Deoxycytidine - therapeutic use | Fluorouracil - adverse effects | Chemotherapy, Adjuvant - adverse effects | Aged, 80 and over | Adult | Deoxycytidine - adverse effects | Female | Pancreatic Neoplasms - mortality | Chemoradiotherapy - methods | Pancreatic Neoplasms - pathology | Antimetabolites, Antineoplastic - therapeutic use | Guideline Adherence | Adenocarcinoma - therapy | Survival Analysis | Aged | Deoxycytidine - analogs & derivatives | Adenocarcinoma - mortality | Pancreatic Neoplasms - therapy | Adenocarcinoma | Care and treatment | Nuclear radiation | Pancreatic cancer | Patient outcomes | Analysis | Adjuvant treatment | Clinical trials | Cancer | Index Medicus | HEAD | PATIENTS | QUALITY ASSURANCE | FAILURES | PANCREAS | INFUSION | TOXICITY | CHEMOTHERAPY | MULTIVARIATE ANALYSIS | RECOMMENDATIONS | CARCINOMAS | RADIOLOGY AND NUCLEAR MEDICINE | RADIOTHERAPY | COMBINED THERAPY | HAZARDS | pancreatic adenocarcinoma | adjuvant therapy | chemoradiotherapy | quality assurance
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 8, pp. 979 - 989
Journal Article
by de Boer, Stephanie M and Powell, Melanie E and Mileshkin, Linda and Katsaros, Dionyssios and Bessette, Paul and Haie-Meder, Christine and Ottevanger, Petronella B and Ledermann, Jonathan A and Khaw, Pearly and Colombo, Alessandro and Fyles, Anthony and Baron, Marie-Helene and Jürgenliemk-Schulz, Ina M and Kitchener, Henry C and Nijman, Hans W and Wilson, Godfrey and Brooks, Susan and Carinelli, Silvestro and Provencher, Diane and Hanzen, Chantal and Lutgens, Ludy C H W and Smit, Vincent T H B M and Singh, Naveena and Do, Viet and D'Amico, Romerai and Nout, Remi A and Feeney, Amanda and Verhoeven-Adema, Karen W and Putter, Hein and Creutzberg, Carien L and McCormack, Mary and Whitmarsh, Karen and Allerton, Rozenn and Gregory, Deborah and Symonds, Paul and Hoskin, Peter J and Adusumalli, Madhavi and Anand, Anjana and Wade, Robert and Stewart, Alexandra and Taylor, Wendy and Kruitwagen, Roy F.P.M and Hollema, Harry and Pras, Elizabeth and Snyers, An and Stalpers, Lukas and Jobsen, Jan J and Slot, Annerie and Mens, Jan-Willem M and Stam, Tanja C and Van Triest, Baukelien and Van der Steen - Banasik, Elzbieta M and De Winter, Karin A.J and Quinn, Michael A and Kolodziej, Ilka and Pyman, Jan and Johnson, Carol and Capp, Anne and Fossati, Roldano and Gribaudo, Sergio and Lissoni, Andrea A and Ferrero, Annamaria and Artioli, Grazia and Davidson, Cathy and McLachlin, C. Meg and Ghatage, Prafull and Rittenberg, Paula V.C and Souhami, Luis and Thomas, Gillian and Duvillard, Pierre and Berton-Rigaud, Dominique and Tubiana-Mathieu, Nicole and PORTEC Study Grp and PORTEC study group
The Lancet Oncology, ISSN 1470-2045, 03/2018, Volume 19, Issue 3, pp. 295 - 309
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2012, Volume 30, Issue 3, pp. 268 - 273
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 8, pp. 1114 - 1126
Summary Background About 15% of patients with endometrial cancer have high-risk features and are at increased risk of distant metastases and endometrial... 
Hematology, Oncology and Palliative Medicine | CARCINOMA PATIENTS | EXTERNAL-BEAM RADIOTHERAPY | GYNECOLOGIC-ONCOLOGY-GROUP | ONCOLOGY | PELVIC RADIATION-THERAPY | EUROPEAN-ORGANIZATION | STAGE-I | OVARIAN-CANCER | INTERMEDIATE-RISK | III TRIAL | CHEMOTHERAPY | Endometrial Neoplasms - radiotherapy | Prognosis | Follow-Up Studies | Humans | Middle Aged | Gastrointestinal Diseases - etiology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Adenocarcinoma, Clear Cell - radiotherapy | Chemoradiotherapy, Adjuvant - adverse effects | Nervous System Diseases - diagnosis | Case-Control Studies | Gastrointestinal Diseases - diagnosis | Cisplatin - administration & dosage | Neoplasm Grading | Radiotherapy, Adjuvant - adverse effects | Cystadenocarcinoma, Serous - therapy | Female | Paclitaxel - administration & dosage | Cystadenocarcinoma, Serous - secondary | Neoplasm Invasiveness | Carboplatin - administration & dosage | Survival Rate | Lymphatic Metastasis | Hematologic Diseases - diagnosis | Adenocarcinoma, Clear Cell - secondary | Hematologic Diseases - etiology | Adenocarcinoma, Clear Cell - therapy | Endometrial Neoplasms - therapy | Nervous System Diseases - etiology | Quality of Life | Endometrial Neoplasms - pathology | Aged | Neoplasm Staging | Cystadenocarcinoma, Serous - radiotherapy | Endometrial cancer | Oncology, Experimental | Radiation | Metastasis | Research | Radiotherapy | Health aspects | Risk factors | Cancer | Index Medicus
Journal Article
Cancer, ISSN 0008-543X, 11/2017, Volume 123, Issue 21, pp. 4147 - 4157
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2012, Volume 366, Issue 22, pp. 2074 - 2084
Journal Article